Guido Krebiehl, PhD
Biocrates is a leading biotech company in the field of metabolic biomarker research and kit development. Using a targeted, mass spectrometry-based metabolomics approach, Biocrates identifies and quantifies endogenous metabolites in body fluid or tissue samples and develops them into powerful biomarkers. Biocrates has a strong background in biological sciences and (bio-) informatics as well as long-standing experience in analytical method development, method application, data analysis, and project management. Biocrates is well equipped with a state-of-the-art mass spectrometry platform that, in combination with its comprehensive methodological knowledge, allows the accurate quantification of a vast range of metabolites across several biochemical classes in a targeted metabolomics approach. Biocrates has been involved in various international and national research consortia and by applying its analytical services, directly contributed to neonatal research projects like e.g. the EU-funded NEOBRAIN project.